Media Articles Related to Ablavar (Gadofosveset)
Third Annual EU Device and Diagnostic Regulation Conference, June 12-13, 2014, Brussels
Source: Conferences News From Medical News Today [2014.04.03]
For the third straight year, Q1 Productions will host the EU Device and Diagnostic Regulation Conference, offering attendees an exclusive opportunity to participate in interactive discussions with...
New diagnostic test for bowel diseases
Source: Colorectal Cancer News From Medical News Today [2014.03.31]
A novel method for distinguishing different types of bowel disease using the stool samples of patients has been created by a group of researchers in the UK.
New app turns any smartphone into a portable medical diagnostic device
Source: Urology / Nephrology News From Medical News Today [2014.03.22]
A recently-developed mobile phone application could make monitoring conditions such as diabetes, kidney disease, and urinary tract infections much clearer and easier for both patients and doctors...
New diagnostic, treatment approach for aggressive prostate cancer suggested by cholesterol-metabolism study
Source: Cholesterol News From Medical News Today [2014.03.06]
Researchers have discovered a link between prostate cancer aggressiveness and the accumulation of a compound produced when cholesterol is metabolized in cells, findings that could bring new...
Schizophrenia enters the molecular diagnostics era
Source: Schizophrenia News From Medical News Today [2014.02.13]
With a drop of blood and some laboratory analyses, doctors have been able to tell patients whether they suffer from diabetes or some sort of cancer.
Published Studies Related to Ablavar (Gadofosveset)
Contrast-enhanced whole-heart MR coronary angiography at 3.0 T using the intravascular contrast agent gadofosveset. [2009.07]
OBJECTIVES: The purpose of this study was to compare contrast-enhanced (CE) whole-heart coronary magnetic resonance angiography (MRA) at 3.0 T using gadofosveset to noncontrast-enhanced steady-state free precession (SSFP) coronary MRA at 1.5 T... CONCLUSIONS: CE whole-heart coronary MRA at 3.0 T demonstrated higher overall CNR between coronary blood and myocardium and an improved image quality of the distal coronary segments compared with noncontrast-enhanced SSFP coronary MRA at 1.5 T.
Safety and efficacy of gadofosveset-enhanced MR angiography for evaluation of pedal arterial disease: multicenter comparative phase 3 study. [2008.01]
CONCLUSION: Because of markedly better efficacy than no contrast agent and a minimal and transient side-effect profile, 0.03 mmol/kg of gadofosveset was found safe and effective for MR angiography of patients with pedal arterial disease.
Contrast-enhanced MRA of the renal and aorto-iliac-femoral arteries: comparison of gadobenate dimeglumine and gadofosveset trisodium. [2011.02]
RATIONALE AND OBJECTIVES: Dedicated contrast agents are now available for contrast-enhanced magnetic resonance angiography (CE-MRA). This study retrospectively compares the safety and diagnostic performance data from Phase III regulatory trials performed to evaluate gadobenate dimeglumine (MultiHance((R))) and gadofosveset trisodium (Vasovist(R))) for renal and peripheral CE-MRA... CONCLUSION: The diagnostic performance of CE-MRA for the detection of significant steno-occlusive disease is similar with gadofosveset and gadobenate dimeglumine although the rate of adverse events appears higher with gadofosveset. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
CMR assessment of endothelial damage and angiogenesis in porcine coronary arteries using gadofosveset. [2011.01.26]
CONCLUSION: Contrast enhanced coronary CMR with gadofosveset can detect experimentally induced endothelial damage and angiogenesis in the porcine coronary artery wall.
Diffusion magnetic resonance imaging with gadofosveset trisodium as a negative contrast agent for lymph node metastases assessment. [2011.01]
PURPOSE: The aim of this study was to assess the feasibility of using intravenously administered gadofosveset trisodium as a negative contrast agent for lymph node (LN) assessment with diffusion-weighted imaging (DWI) using a VX2 tumor model in rabbits... CONCLUSION: The SI of metastatic LNs at DWI is less suppressed than that of nonmetastatic LNs after the intravenous administration of gadofosveset trisodium. Therefore, intravenously administered gadofosveset trisodium shows promise for use as a negative contrast agent for discriminating metastatic from nonmetastatic LNs at DWI.
Clinical Trials Related to Ablavar (Gadofosveset)
LMI - Ablavar - 401 - Study of Incidence of Nephrogenic Systemic Fibrosis(NSF) in Kidney Disease Patients Undergoing MRI With Ablavar [Not yet recruiting]
In this phase 4 study, all patients will receive 1 dose of Ablavar as part of an MRI
examination in their routine clinical management.
A standardized NSF questionnaire will be administered to the patient at various time points
post-dose. At 1 year and 2 years (+1 or - 1 month) patients will return to the clinic for a
limited examination for skin abnormalities and formal review of signs and symptoms
suggestive of NSF.
Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants [Recruiting]
The purpose of this study is to assess the image quality of Ablavar-enhanced MR angiography
of the central veins of the chest, and to determine whether dose reduction can be performed
while maintaining image quality. This will be a prospective randomized study, in which
healthy volunteers will be recruited to undergo a central veins magnetic resonance angiogram
(MRA). They will receive either the FDA-approved dose or a lower dose of Ablavar.
Quantitative and qualitative analysis will be performed on the images.
Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI) [Recruiting]
Patients with chronic liver disease are at high risk of developing liver scarring
(fibrosis), with ultimate risks of cirrhosis and liver cancer that may require liver
transplant. The investigators would like to develop non invasive advanced Magnetic Resonance
Imaging (MRI) techniques (MR diffusion, perfusion and elastography) to assess the degree of
liver damage in patients with chronic liver disease. These techniques combined could reach
high diagnostic performance for detection of liver fibrosis; and could decrease the number
of liver biopsies, which have risks and sample only a small portion of the liver.
Nodal Staging in Breast Cancer With MRL [Recruiting]
The aim of this study is to examine the diagnostic performance of gadofosveset enhanced
magnetic resonance imaging lymphography (MRL).
The diagnostic performance of MRL will be determined on the basis of a node-to-node matching
of imaged nodes to the definitive histopathology. The pathologic examination of the sentinel
lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) will be regarded as the
golden standard for nodal involvement.
Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer [Recruiting]